The pFUSE plasmid collection has been designed to change a monoclonal antibody (mAb) from one isotype to another (IgA, IgD, IgE, IgG and IgM). Therefore, they enable the generation of mAbs with the same antigen affinity but with different effector functions including ADCC (antibody-dependent cellular cytotoxicity), ADCP (antibody-dependent cellular phagocytosis), or CDC (complement dependent cytotoxicity) activity.
This plasmid collection includes:
pFUSE-CLIg family: encodes the constant region of either the kappa or lambda light chain (CL) from a variety of species.
pFUSE-CHIg family: encodes the constant region of a number of Ig isotype heavy chains (CH) from a variety of species. This family also includes:
- pFUSE-Lucia-CHIg plasmids: facilitate the detection and quantification of recombinant antibodies.
- Engineered pFUSE-CHIg plasmids: encode mutant forms of the constant regions from the heavy chain of human IgG1 to modify effector function.
Each plasmid in this collection has a unique multiple cloning site (MCS) upstream of the constant region to facilitate the insertion of the variable region of any given mAb.
When pFUSE-CLIg and pFUSE-CHIg are transfected in combination, they can be used to produce entire antibodies from either fragment antigen-binding (Fab) or single-chain variable fragment (scFv) fragments. The whole recombinant mAb can either be chimeric, humanized or fully human depending on the nature of the variable region
COVID-19 related research
Recombinant neutralizing monoclonal antibodies targeting SARS-CoV-2 antigens, such as the spike (S) glycoprotein and the nucleoprotein (N), can be used in detection or neutralization assays to better understand the mode of action (MOA) of this virus. Additionally, they represent a promising approach for the treatment and prevention of COVID-19.